AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)